First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer Meeting Abstract
| Authors: | Saura, C.; Sanz, L.; Kim, J.; Jhaveri, K. L.; Guerrero, A.; Ortega, P. T.; Schott, A. F.; Curigliano, G.; Perez, C. A.; Nanda, R.; Hamilton, E. P.; Henry, J. T.; Wisinski, K. B.; Sammons, S. L.; Segar, J. M.; Aix, S. P.; Sirven, M. B.; Spira, A. I.; Schram, A. M.; Varkaris, A. |
| Abstract Title: | First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406033 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS1128 |
| Notes: | Meeting Abstract: TPS1128 -- Source: Wos |
